Insmed (MEX:INSM) Tariff Resilience Score: 7/10 (As of Jul. 06, 2026)


MEX:INSM Insmed Inc MEX:INSM
68 GF Score
Price MXN3,760.00
GF Value MXN5,773.42
! 4 Warning Signs
View Full Analysis

What is Insmed Tariff Resilience Score?

Insmed MEX:INSM 68 Tariff Resilience Score is 7 as of Jul. 06, 2026. GuruFocus rates MEX:INSM with a GF Score™ of 68/100 and a GF Value™ of MXN5,773.42. The stock has 4 warning signs investors should review. Among 1,369 Biotechnology companies, Insmed ranks better than 90.36% on this metric.

Insmed has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Insmed has Insmed Inc, a biotech firm, has moderate tariff exposure. Its products, primarily pharmaceuticals, often benefit from tariff exemptions. The company has a diversified supply chain and can source materials from multiple regions, reducing vulnerability to trade disruptions.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Insmed might have Highly Resilient.

Insmed  (MEX:INSM) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Insmed Tariff Resilience Score Related Terms

MEX:INSM vs INCY, BNTX, ROIV: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Insmed's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Insmed Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Insmed's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Insmed's Tariff Resilience Score falls into.


MEX:INSM
68GF Score
Insmed Inc MEX:INSM
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Insmed (MEX:INSM) has a Tariff Resilience Score of 7 as of Jul. 06, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Insmed ranks #132 out of 1369 companies in the Biotechnology industry, placing it in the top 9.6%.
Is Insmed's Tariff Resilience Score too high?
Insmed's current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. Insmed's value of 7 is 75% above this industry median. Based on the distribution chart, Insmed ranks #132 out of 1369 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Insmed has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does Insmed's Tariff Resilience Score compare to INCY and BNTX?
According to the Biotechnology industry distribution chart, Insmed ranks #132 out of 1369 companies for Tariff Resilience Score. This places Insmed in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Insmed's value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,369 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Insmed's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Insmed's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insmed stock overvalued right now?
Insmed (MEX:INSM) has a current Tariff Resilience Score of 7. The stock's GF Value™ is MXN5,773.42, compared to a current price of MXN3,760.00 — trading 34.9% below its estimated fair value. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. Insmed's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Insmed (MEX:INSM), the current Tariff Resilience Score is 7 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Insmed (MEX:INSM) Overvalued in 2026?

Based on GuruFocus' analysis, Insmed stock appears to be undervalued. The current stock price of MXN3,760.00 is trading 34.9% below its estimated GF Value™ of MXN5,773.42.

Key valuation signals for MEX:INSM:

  • Tariff Resilience Score: 7
  • GF Value™: MXN5,773.42 vs. price of MXN3,760.00 (34.9% below fair value)
  • GF Score™: 68/100 with 4 warning signs
  • Industry Position: 75% above the Biotechnology median (#132 of 1369)

No single metric tells the full story. See the MEX:INSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Insmed Business Description

Address 700 US Highway 202/206, Bridgewater, NJ, USA, 08807
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
68GF Score

Get the complete analysis for MEX:INSM

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN3,760.00
Price
MXN5,773.42
GF Value